Abstract:WHAT IS KNOWN AND OBJECTIVE: Like many countries in the world, China is also facing growing drug expenditures year by year. In particular, the rising cost of prescription drugs has been one of the critical factors leading to the serious burden on health insurance programs. The high cost of prescription drugs not only threatens the health budget but also limits the nation's investment in other public sectors. China implemented the National Centralized Drug Procurement (NCDP) policy, also known as the "4 + 7" policy, in tertiary hospitals in various provinces and cities across the country on 18 December 2019, aiming to lessen personal and national health insurance burdens by reducing drug procurement prices. The aim of this study is to explore the impact of the implementation of the NCDP policy on the drug expenditures of patients treated in outpatient and emergency departments and on national health insurance expenditures.METHODS: This study adopts interrupted time series (ITS) to evaluate the impact of China's implementation of the NCDP policy on the drug expenditures of patients treated in outpatient and emergency departments in a tertiary hospital. The NCDP policy was officially implemented on 18 December 2019. A segmented regression model is utilized to analyse the average monthly drug expenditures of patients treated in outpatient and emergency departments from January 2018 to June 2021, including the average monthly per-visit drug expenditures of all patients and the average monthly per-visit drug expenditures of patients who paid for drugs with health insurance and those who did not use health insurance.RESULTS: After the implementation of the NCDP policy, the overall average monthly per-visit drug expenditures of patients treated in outpatient and emergency departments were immediately reduced by 233.954 CNY (p < 0.01). Compared with the continued downward trend for drug expenditures before the implementation of the NCDP policy, the long-term trend after policy implementation was not obvious (p = 0.051973>0.05). Similarly, the average monthly per-visit drug expenditures of patients treated in outpatient and emergency departments who use health insurance to procure drugs also immediately decreased by 505.287 CNY (p < 0.01), but the long-term trends before (p = 0.469>0.05) and after policy implementation (p = 0.51>0.05) did not exhibit obvious change. For the average monthly per-visit drug expenditures of patients treated in outpatient and emergency departments who did not use health insurance, the implementation of the NCDP policy did not produce an immediate reduction in drug expenditures (p = 0.3603>0.05). Although the average monthly per-visit drug expenditures decreased by 9.078 CNY (p < 0.01) before policy implementation, this trend ended after the policy was implemented (p = 0.0735>0.05), and no other changes were triggered.WHAT IS NEW AND CONCLUSION: This study reviews the data for a period of time before and after the implementation of the NCDP policy. The policy is shown to significantly decrease the average monthly per-visit drug expenditures of patients treated in outpatient and emergency departments.

The Impact of China's National Essential Medicine Policy and Its Implications for Urban Outpatients: A Multivariate Difference-in-Differences Study.

Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level‐A hospital in China: A single centre, interrupted time series

Retrospective Survey of the Efficacy of Mandatory Implementation of the Essential Medicine Policy in the Primary Healthcare Setting in China: Failure to Promote the Rational Use of Antibiotics in Clinics.

The Impact of the National Essential Medicines Policy on Rational Drug Use in Primary Care Institutions in Jiangsu Province of China.

Short- and long-term impacts of the National Essential Medicines Policy on drug availability, price, and usage in a deprived rural county in southwestern China: an interrupted time series analysis across 8 years

Influence of National Essential Public Health Services Policy on Expenditure for Hypertension in China: A Difference-in-Difference Analysis

The Impact of China's National Essential Medicine System on Improving Rational Drug Use in Primary Health Care Facilities: an Empirical Study in Four Provinces.

The Impact of Increasing Expenditure on National Essential Public Health Services on the Medical Costs of Hypertension in China: A Difference-in-difference Analysis

A Preliminary Analysis of the Effect of the New Rural Cooperative Medical Scheme on Inpatient Care at a County Hospital

The Effect of Essential Medicines Programme on Rational Use of Medicines in China

A Description of Outpatient Drug Use in Rural China: Evidence of Differences Due to Insurance Coverage.

Impact of the national essential medicine system upon operations of primary health institutions: an empirical study in four provinces and cities

The Impact of Prescribing Monitoring Policy on Drug Use and Expenditures in China: A Multi-center Interrupted Time Series Study.

Impact of China's Urban Resident Basic Medical Insurance on Health Care Utilization and Expenditure

Short-term and Long-Term Unintended Impacts of a Pilot Reform on Beijing's Zero Markup Drug Policy: a Propensity Score-Matched Study

Short-term and long-term unintended impacts of a pilot reform on Beijing’s zero markup drug policy: a propensity score-matched study

Impact of the Zero-Mark-up Drug Policy on Drug-Related Expenditures and Use in Public Hospitals, 2016–2018: an Interrupted Time Series Study in Shaanxi

Trends analysis for drug utilization in county public hospitals: a sample study of the pilot area of health care reform in China

The Financial Impact of the ‘Zero-Markup Policy for Essential Drugs’ on Patients in County Hospitals in Western Rural China

Evaluation, in Three Provinces, of the Introduction and Impact of China'S National Essential Medicines Scheme

Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program